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Background: Axillary lymph node dissection (ALND) in patients with breast cancer has the potential to induce side-
effects, including upper-limb lymphedema. Axillary reverse mapping (ARM) is a technique that enables
discrimination of the lymphatic drainage of the breast from that of the upper limb in the axillary lymph node (LN)
basin. If lymphedema is caused by removing these lymphatics and nodes in the upper limb, the possibility of
identifying these lymphatics would enable surgeons to preserve them. The aim of this study is to determine the
clinical relevance of selective axillary LN and lymphatic preservation by means of ARM. To minimize the risk of
overlooking tumor-positive ARM nodes and the associated risk of undertreatment, we will only include patients
with a tumor-positive sentinel lymph node (SLN). Patients who are candidates for ALND because of a proven
positive axillary LN at clinical examination can be included in a registration study.
Methods/design: The study will enroll 280 patients diagnosed with SLN biopsy-proven metastasis of invasive
breast cancer with an indication for a completion ALND. Patients will be randomized to undergo standard ALND or
an ALND in which the ARM nodes and their corresponding lymphatics will be left in situ. Primary outcome is the
presence of axillary surgery-related lymphedema at 6, 12, and 24 months post-operatively, measured by the water-
displacement method. Secondary outcome measures include pain, paresthesia, numbness, and loss of shoulder
mobility, quality of life, and axillary recurrence risk.
Discussion: The benefit of ALND in patients with a positive SLN is a subject of debate. For many patients, an ALND
will remain the treatment of choice. This multicenter randomized trial will provide evidence of whether or not
axillary LN preservation by means of ARM decreases the side-effects of an ALND. Enrolment of patients will start in
April 2013 in five breast-cancer centers in the Netherlands, and is expected to conclude by April 2016.
Trial registration: TC3698
Keywords: Breast cancer, Axillary lymph node dissection, Breast cancer-related lymphedema, Axillary reverse
mappingBackground
Axillary lymph node dissection (ALND) for patients with
breast cancer has the potential to cause side-effects, includ-
ing pain, numbness or paresthesia, arm/shoulder mobility
restriction, and lymphedema [1]. Arm lymphedema has
been documented in 7 to 77% of patients who undergo
ALND [2,3]. The incidence of lymphedema depends on* Correspondence: pgobardhan@amphia.nl
2Department of Surgery, Amphia Hospital, Molengracht 21, 4818, CK Breda,
The Netherlands
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distribution, and reproduction in any mediumwhether ALND has been combined with subsequent
radiotherapy, but also on the definition of ALND used.
Sentinel lymph node biopsy (SLNB) represents the
standard of care for axillary node staging in patients
with early-stage, clinically node-negative breast cancer
(cT1 to 2N0). The goals of SLNB are to reduce the
morbidity from breast-cancer surgery by avoiding
unnecessary ALND and to improve staging of the
regional LNs. However, in a selected group of patients,
ALND is still indicated.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Klompenhouwer et al. Trials 2013, 14:111 Page 2 of 7
http://www.trialsjournal.com/content/14/1/111Axillary reverse mapping (ARM) is a recently developed
technique that enables surgeons to discriminate the
lymphatic drainage pattern of the breast from that of the
upper limb. The concept of ARM is to map the drainage
of the upper limb to determine the anatomical variation in
these lymphatics and thus create a road map for their
preservation. If lymphedema is caused by removing the
lymphatics and nodes of the upper limb, the possibility of
identifying these lymphatics would enable surgeons to pre-
serve them [4]. The ARM technique can be performed by
using blue dye, fluorescent dye, or a radioisotope. In the
past few years, several groups have reported their first ex-
periences with this relatively new technique [5-13]. A re-
view by Ngochi on this topic [14] clearly described the
ARM techniques that are currently available. Studies on
ARM using blue dye reported identification rates varying
between 50 and 89% [5-10], and for isotope and fluores-
cent dyes, these rates are 91 to 100% [11,13] and 88% [12]
respectively. The latter two visualization techniques have
the advantage of not leaving a ‘blue tattoo’ on the patient’s
skin. However, there is limited information on the use of
isotopes and fluorescent dyes, and they require the use of
expensive equipment during surgery.
Between October 2009 and June 2011, we performed a
pilot study using blue dye for visualizing LN drainage of
the upper limb [15]. Patients with invasive breast cancer
and an indication for ALND were enrolled in the study,
and these comprised 50 patients with a tumor-positive
SLN and 43 patients who had axillary LN metastases
proven by pre-operative cytology. During surgery, ARM
nodes were identified and removed first, followed by
ALND (at least level I to II). No significant differences
were seen in the visualization rate of ARM nodes be-
tween the groups (86 and 94% respectively, P = 0.196).
In the group of patients with a positive SLN, none of the
ARM nodes contained metastases, whereas 11 (22%) of
the ARM nodes in the group with axillary metastases
proven by pre-operative cytology contained metastases
(P = 0.001). Patients receiving neoadjuvant chemother-
apy had a significantly lower risk of additional axillary
LN metastases (24.6 versus 44.4%, P = 0.046). These re-
sults are largely in accordance with other studies. Boneti
et al. [8], Thompson et al. [7], and Casbona et al. [10]
found no tumor deposits in the ARM nodes even when
the patients had positive axillary nodes in the initial
series. However, Nos et al. [6] found metastases in 14%
of the ARM nodes (3 of 21 patients), all of which were
associated with extensive axillary LN metastasis. Noguchi
et al. [12] found ARM node metastases in three of seven
patients who underwent ALND, and all three patients had
a clinically positive axilla (N1/N2). Based on our results
and those from the literature, we conclude that the ARM
procedure using blue dye is technically feasible and has a
high visualization rate, and that its use might beconsidered in patients with a positive SLN. Neverthe-
less, more research is needed to determine the safety of
ARM in patients with clinically positive LNs.
Despite these promising results, there are some prob-
lems that need to be considered before ARM can be
used in routine clinical practice. The currently available
techniques are insufficient to identity the upper-limb
LNs in some patients. The relevance of the ARM pro-
cedure is based on the assumption that the lymphatic
pathways from the upper limb are not involved in me-
tastasis of the primary breast cancer [5]; however, in a
minority of patients, the SLN draining of the breast may
be the same as the ARM node draining the upper limb.
This may explain why the ARM nodes may be involved
with metastatic foci in patients with clinically axillary LN
metastases. These issues may represent an important
drawback for the implementation of the ARM procedure.
Boneti et al. recently published a phase II trial of
ARM with promising results [16]. The study showed
that preserving the ARM nodes in a clinically negative
axilla is safe, and results in a low incidence of post-
operative lymphedema in patients undergoing ALND
and SLNB. However, further studies are needed before
this technique can be adopted as a standard procedure
during complementary ALND (cALND) in the surgical
treatment of breast cancer.
In this paper, we present the design for a multicenter
randomized controlled trial to determine the clinical
relevance and safety of selectively sparing upper-limb ax-
illary LNs and their corresponding lymphatics by means
of ARM. To minimize the risk of under-treatment due to
non-removal of possible ARM node metastases, we will
only include patients based on a tumor-positive SLN.
Methods/design
The aim of the ARM trial is to determine the usefulness of
the ARM technique in identifying and sparing the upper
limb-related axillary LNs, and its ability to reduce the risk
of lymphedema of the upper limb. After determining the
indication for a cALND basis on a tumor-positive SLN,
patients will be randomly allocated to one of two groups:
ALND with preservation of the upper limb-related
axillary LNs (ARM-ALND) and a level I-II ALND
(standard ALND).
Patients who are candidates for a primary axillary lymph
node dissection (pALND), based on axillary metastases
proven by pre-operative cytology, can be included in the
registration study to confirm the feasibility of the procedure
and to perform a further subgroup analysis. A schematic
overview of the trial is given in Figure 1.
Participants
Female patients aged over 18 years presenting with inva-
sive breast cancer and an indication for a cALND based
Figure 1 Flow chart of axillary reverse mapping (ARM) trial. ALND, Axillary lymph node dissection; cALND, complementary axillary lymph
node dissection based on a tumor-positive sentinel node; pALND, primary axillary lymph node dissection based on a tumor-positive axilla proven
by pre-operative cytology; ARM-ALND axillary lymph node dissection with preservation of the upper limb-related axillary lymph nodes; standard
ALND, level I-II axillary lymph node dissection.
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The indication for the ALND should be made by a
multidisciplinary team including an oncologic surgeon, a
medical oncologist, a pathologist, a radiologist, and a
radiotherapist. Informed consent will be obtained from
all patients. Exclusion criteria are: indication for pALND
based on a clinical positive axilla; contraindication for
SLNB; an adverse event during the previous SLNB; history
of breast cancer or axillary surgery; or pregnancy.
Patients who undergo an ALND based on a clinically
positive axilla can participate in the registration study, in
which patients will undergo ARM during ALND. In this
group of patients, no attempt will be made to spare LNs
or lymphatics.
Objectives
The hypothesis is that patients undergoing ARM-ALND
will have fewer post-operative complications than patients
undergoing standard ALND. The post-operative complica-
tions that will be measured are the occurrence of breast
cancer-related lymphedema (BCRL) and paresthesia/
numbness, pain, and shoulder immobility. The hypothesis
is that a reduction in the risk of post-operative compli-
cations in patients undergoing ARM-ALND will result
in a better quality of life compared with those undergo-
ing standard ALND. Based on the results of our feasi-
bility study, in which no LN metastasis where found inthe patients with tumor-positive SLN, it is expected
that the axillary recurrence risk in the ARM-ALND
group will be comparable with the risk in the standard
ALND group.
Research question
1. Will there be fewer post-operative complications
after ARM-ALND compared with standard ALND
in patients with an indication for a cALND based on
a positive SLNB? Post-operative complications are
expected to include the following. primary
complication: BCRL; secondary: pain, paresthesia/
numbness, and loss of shoulder mobility.
2. Will the possible reductions in these post-operative
complications have a positive effect on the quality of
life (QoL)?
3. Will patients undergoing ARM-ALND have a similar
risk of axillary recurrence as the patients undergoing
standard ALND?
Randomization
Randomization will be performed using a web-based
randomization system, and will be stratified by center.
This randomization application and the internet-based
help service will be available 24 hours a day, 7 days a week.
Because of practical considerations, the randomization will
Subcutaneous injection of 2 ml blue 
dye into the upper inner arm along 
the medial intermuscular groove of  
the ipsilateral arm 
Massage of the site of injection and 
elevation for a few minutes
Covering of the patient with sterile 
drapes
ARM-ALND Standard ALND
Start ALND by identifying ARM lymph 
nodes/lymphatics
Separate analysis by the pathologist 
of all lymph nodes 
Figure 2 Axillary reverse mapping (ARM) procedure.
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formed consent. Based on our previous experience with
the ARM procedure, we expect that identification or
preservation of the ARM nodes/lymphatics will not be
possible in 5 to 15% of the randomized patients. In such
cases, the standard ALND will be performed, if possible,
and the ARM nodes/lymphatics will be separately re-
moved and sent for analysis. These patients will be
included in the analysis in accordance with the intention-
to-treat principle, but excluded from the sensitivity
analysis. (Figure 1) (more information can be found at
www.armstudie.nl).
Interventions
Surgeons familiar with the ARM procedure will perform
the ALND. In our feasibility study (Amphia Hospital
Breda, the Netherlands), the learning curve for performing
the ARM procedure was very small (barely measureable),
and the overall identification rate of the upper-limb LNs
was up to 94%. Based on these results, we consider an on-
cologic breast surgeon should be capable of performing an
ARM procedure once they have performed five proce-
dures under the supervision of one of the oncologic
surgeons (EL or PG) from the Amphia Hospital Breda.
The procedure will be performed under general
anesthesia. For the procedure, approximately 2 ml of
blue patent V dye (Laboratoire Guerbet, Aulnay-sous-
Bois, France) from a stock solution of 25 mg/ml is
injected subcutaneously into the inner arm, along the
medial intermuscular groove of the ipsilateral arm. This
dye is identical to the dye used to perform an SLNB.
After injection, the site of injection is massaged and the
arm elevated for a few minutes to enhance lymphatic
drainage of this limb. Next, the patient is covered with
sterile drapes, and the ALND can be started.
The technical part of the operation is identical to a
normal level I to II ALND, except for the first part of
the operation. After incision, the blue-stained LNs and
lymphatics are identified. In the ARM-ALND group, the
blue-stained LNs and lymphatics will be spared, then a
normal ALND will be performed. In the standard ALND
group, a normal ALND will be performed without spar-
ing the upper-limb lymphatics and LNs. The pathologist
will separately analyze the LNs (level I to II nodes and
ARM nodes, Figure 2).
Settings and location
The study is a multicenter randomized controlled trial,
which will be conducted in the Netherlands. Already
five dedicated breast-cancer centers in the Netherlands
are willing to participate. These are: Amphia Hospital,
Breda; Catharina Hospital, Eindhoven; Haga Hospital,
The Hague; Hospital Gelderse Vallei, Ede; and Albert
Schweitzer Hospital, Dordrecht.Patients eligible for inclusion will be enrolled by the
breast surgeon at the outpatient clinic, after providing
informed consent.
Primary and secondary outcome measures
The primary outcome will be the occurrence of lymph-
edema in the upper limb. Lymphedema will be measured
s at 6, 12 and 24 months, using the following two
techniques.
1) The water-displacement method. This method is
regarded as the gold standard for the measurement of
lymphedema. For the assessment of upper-limb
volume, an arm volume meter will be used (NV
Varitex Haarlem, The Netherlands). This method has
high reproducibility [17]. Both upper limbs will be
measured pre-operatively and post-operatively.
Lymphedema is defined as a difference in limb volume
of greater than 200 ml between the treated and
untreated side, as described by Lopez Penha et al. [18].
2) Circumference method. The arm circumference will
be measured at four sites: metacarpophalangeal




























CRF, case report form; PQ, participant questionnaire.
aThe volume, circumference and mobility of the arm will be measured
pre-operatively.
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epicondyle, and 150 mm proximal of the epicondyle.
A difference of more than 20 mm between the
affected and contralateral arm is considered
clinically significant.
The secondary endpoints will be measured at 6, 12,
and 24 months and comprise the following:
1) Paresthesia/numbness. This will be assessed with the
aid of a standardized questionnaire developed for
patients with breast cancer [19].
2) Pain. This will be measured using a visual analog
scale.
3) Loss of shoulder mobility. The shoulder function of
the affected upper limb will be compared with the
unaffected one. Loss of abduction of more than 20
degrees will be considered abnormal.
4) Quality of life. This will be assessed by a
standardized questionnaire developed for patients
with breast cancer [21]. This large questionnaire
includes the WHOQOL-Bref.
5) Locoregional recurrence rate: This will be assessed
by a physical examination during follow-up. In cases
where there is suspicion of recurrence,
ultrasonography (with or without biopsy) will be
performed.
Data collection
A nurse practitioner or clinical investigator (depending
on the local organization of the participating hospital)
will be responsible for the pre-operative and post-
operative data collection. The surgeon who performed
the ALND will be responsible for the peri-operative data
collection. Data will be stored anonymously under a
unique trial number. The principal investigators (EL and
PG) will have access to the data. All data will be collected
in an online case report form and an online participant
questionnaire (PQ). The timetable and source of the data
collection is listed in Table 1.
Blinding
The qualified oncologic breast surgeon will perform the
procedure and therefore cannot be blinded. The patient
and the person responsible for the post-operative data
collection and measurements will not be aware of the
performed procedure (double-blind procedure).
Statistics
Sample size
The clinically relevant amount of lymphedema is stated
as a volume difference of 200 ml or more between both
arms. Primary research shows that the risk of BCRL is
15% in patients undergoing an ALND. It is expected thatARM-ALND will reduce the risk to 5%. Based on these
assumptions, we will need to study 140 subjects in the
standard ALND group and 140 subjects in the ALND-
ARM group to be able to reject the null hypothesis that
the failure rates for experimental and control subjects
are equal with a probability (power) of 0.8. The Type I
error probability associated with this test of the null
hypothesis is 0.05.
Data analysis
We will use an uncorrected χ2 statistic to test the null
hypothesis for the proportion of patients developing
lymphedema in the upper limb. These tests will be
performed after 6, 12, and 24 months. We are interested
in the course of the development of lymphedema, based
on the measurements at each of the three specified time
points. As development of lymphedema has been reported
to occur 2 or more years after surgery, the measurement
of lymphedema at 24 months is considered our primary
endpoint.
To compare continuous data, such as pain and quality of
life, analysis of covariance (ANCOVA) will be performed,
using baseline values as a covariate. Separate analyses
will be performed for the three time points (6, 12 and
24 months). The local recurrence rate in both groups
will be analyzed by the Kaplan-Meier method and com-
pared with the log-rank test. A repeated-measures ana-
lysis will be performed to compare the changes in
continuous data between the two groups, until 2 years
after treatment. It is expected that not only will the
prevalence of lymphedema be higher in the standard
ALND arm, but also that it will occur earlier and will be
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between treatment and time will be included in the
repeated-measures analysis.
All data will be documented and analyzed using SPSS
software (SPSS Inc., Chicago, IL, USA), with the exception
of the repeated-measures analysis, for which SAS software
(SAS Institute, Cary, NC, USA) with the procedure PROC
MIXED. No interim analysis will be performed.
Discussion
Treatment of the axilla in patients with breast cancer has
been a subject of recent debate. More than 50% of patients
with a positive SLN appear to have no further LN involve-
ment [20,21]. Based on these findings, the therapeutic role
of cALND for these patients seems limited [22].
In the late 1990s, the American College of Surgeons
Oncology Group (ACOSOG) Z0011 trial started in the
USA. That trial randomized patients with breast cancer
who had one to three positive SLNs to either cALND or
a ‘wait and see’ policy. The results were recently pub-
lished and no differences in overall survival (OS) or
disease-free survival were seen after a median follow-up
of 6.3 years [23]. Although the results do question the
therapeutic benefit of ALND in SLNB-positive patients,
abandoning ALND is not yet regarded as a standard of
care. Moreover, considering the selected group of pa-
tients in the ACOSOG Z0011 trial, of which the majority
received adjuvant chemotherapy and locoregional radio-
therapy of the breast with inclusion of the lower regions
of the axilla, the safety of omitting ALND in patients not
fulfilling these criteria remains unclear.
A recently published study by Avril et al. [24] failed to
show benefit in event-free survival and OS for post-
menopausal patients with early breast cancer. This study
randomized clinically node-negative post-menopausal
patients with breast cancer to an ALND group or a no-
ALND group. Adjuvant systemic therapy was based on
the primary tumor characteristics.
In other studies, published several years ago, no differ-
ence was found in locoregional disease control, metastasis-
free survival, and OS between patients treated with ALND
and those treated with radiotherapy of the axilla [25].
However, as was the case with standard ALND, axillary
radiotherapy appeared to be associated with an increased
incidence of lymphedema [26,27].
The recently published Dutch guideline for breast-
cancer treatment [28] gives several therapeutic options
for the treatment of the axilla. It says that, in case of
micrometastasis and macrometastasis with a maximum
of two positive SLNs in patients receiving a breast-
sparing therapy in combination with adjuvant systemic
therapy, omission of the cALND can be considered. This
may affect the accrual of the trial. However, there will be
many patients left for whom pALND and cALND willremain the first-choice treatment; for example, in patients
undergoing a mastectomy or in patients with a high risk
of axillary involvement. For these patients, a limited and
more tailored ALND based on the ARM technique might
be a valuable tool to reduce the morbidity associated with
the current ALND technique.
This multicenter randomized trial will provide evidence
on whether or not upper-limb axillary LN preservation by
means of ARM will decrease the side-effects of ALND.
Trials status
This trial was designed in 2011 and 2012. The protocol
passed through multiple amendments. Final approval
from the medical ethics committee (METC) of Maxima
Medisch Centrum, The Netherlands, was obtained on
21 September 2012 (METC number 1226: Centrale
Commissie Mensgebonden Onderzoek (CCMO) number
NL3920201512). This study will be carried out in compli-
ance with the Helsinki Declaration. The trial is registered
in the Dutch trial registration (TC 3698).
Ethics
Patient recruitment will start in April 2013 in seven
breast-cancer centers in the Netherlands. The study will
finish enrolment as soon as 280 patients are included,
and is expected to finish by April 2016. Collection and
analysis of the results will be performed in the following
2 years.
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